Faruqi & Faruqi, LLP Notifies Investors Who Suffered Substantial Losses Investing In AEterna Zentaris Inc. of Upcoming August 14, 2012 Lead Plaintiff Deadline
NEW YORK, Aug. 6, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AEterna Zentaris Inc. ("AEterna" or the "Company") (NasdaqGM: AEZS).
(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )
The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose in a timely manner that AEterna's drug perifosine was not effective in treating colorectal cancer.
On April 2, 2012, AEterna announced that the Phase 3 "X-PECT" (Xeloda® and Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine and capecitabine (Xeloda®) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine and placebo. As a result of this news, the Company's stock plummeted $1.41 per share to close at $0.73 per share on April 2, 2012, a one-day decline of approximately 66% on high volume.
Request more information now by clicking here: www.faruqilaw.com/AEZS
Take Action
If you purchased AEterna securities and would like to discuss your legal rights, visit www.faruqilaw.com/AEZS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding AEterna's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential matter.
FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP
RELATED LINKS
http://www.faruqilaw.com
More by this Source
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
May 18, 2013, 09:00 ET
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vitamin Shoppe, Inc. To Contact The Firm
May 18, 2013, 09:00 ET
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Ventrus Biosciences, Inc. To Contact The Firm
May 18, 2013, 09:00 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.